This Article Full Text Full Text (PDF) All Versions of this Article: 92/12/4590    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Oudoux, A. Articles by Kraeber-Bodéré, F. Search for Related Content PubMed PubMed Citation Articles by Oudoux, A. Articles by Kraeber-Bodéré, F. Related Collections Endocrine Oncology Thyroid

Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy

Nuclear Medicine (A.O., C.A., F.K.-B.), Endocrinology (A.M.), and Endocrine Surgery (E.M.) Departments, University Hospital, 44093 Nantes, France; Nuclear Medicine (P.-Y.S., C.R., F.K.-B.) and Statistic (L.C.) Departments, René Gauducheau Cancer Center, 44805 Nantes, France; Nuclear Medicine Department (C.B., F.B.-C.), University Hospital, 69495 Lyon, France; Nuclear Medicine Department (S.B.), François Baclesse Cancer Center, 14076 Caen, France; Nuclear Medicine Department (J.-P.V.), University Hospital, 38043 Grenoble, France; Oncology Research Department (J.B., J.-F.C., F.K.-B.), Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 601, 44093 Nantes, France; and Garden State Cancer Center (D.M.G.), Center for Molecular Medicine and Immunology, Belleville, New Jersey 07109-0023

Address all correspondence and requests for reprints to: Françoise Kraeber-Bodéré, Oncology Research Department, Institut National de la Santé et de la Recherche Médicale U601, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 1, France. E-mail: francoise.bodere{at}chu-nantes.fr.

Context: Patients with progressive medullary thyroid carcinoma (MTC) undergo multiple imaging procedures for diagnosis of relapse and staging.

Objective: Our objective was to assess the sensitivity and prognostic value of ¹⁸F-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/computed tomography (CT), and the imaging sensitivity of pretargeted iodine-131-radioimmunotherapy (RIT) in patients with progressive MTC.

Design/Setting/Patients: We performed a prospective multicenter study in high-risk patients with rapidly progressing MTC enrolled in a phase-II pretargeted RIT study, as documented by short serum calcitonin (Ct) or carcinoembryonic antigen (CEA) doubling time (DT).

Interventions/Main Outcome Measures: Patients underwent neck-thoracic-abdominal CT, spine and pelvic magnetic resonance imaging, whole-body post-RIT immunoscintigraphy (IS) with iodine-131, and whole-body ¹⁸F-FDG-PET/CT imaging. Imaging sensitivity and the correlation between FDG uptake and biomarkers DT were evaluated.

Results: A total of 33 patients with mean CEA and Ct DTs of 1.90 yr (range 0.21–8.50) and 1.52 yr (range 0.09–6.01), respectively, were evaluated. Sensitivity of FDG-PET/CT was 83% for neck, 85% for mediastinal, 75% for lung, 60% for liver, and 67% for bone metastases; overall sensitivity was 76%. Median standardized uptake value (SUVmax) was 5.23 (2.06–13.90). SUVmax correlated significantly with Ct DT (P = 0.011) and minimal DT (minimal value between CEA DT and Ct DT) (P = 0.027). Overall sensitivity of post-RIT IS, CT, and bone magnetic resonance imaging were 94, 74, and 85%, respectively.

Conclusions: These results demonstrate the value of FDG-PET/CT for staging of patients with progressive MTC, especially in the neck and mediastinum, with possible prognostication by SUV quantification. Post-RIT IS was the most sensitive of the imaging modalities studied prospectively.